Skip to content

Effect of perioperative esketamine bunching management on postoperative pain and gastrointestinal function of cervical cancer

Effect of perioperative esketamine bunching management on postoperative pain and gastrointestinal function of cervical cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073125
Enrollment
Unknown
Registered
2023-07-03
Start date
2023-07-03
Completion date
Unknown
Last updated
2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative gastrointestinal dysfunction

Interventions

Control group:Normal saline was pumped,PCIA (sufentanil 3µ g/kg)
Intervention group 1: Esketamine group1(Preoperative: 0.25 mg/kg, maintained at 0.15 mg · kg-1 · h-1, PCIA (sufentanil 2 µ g/kg+esketamine 1.5 mg/kg)
Intervention group 2: Esketamine group2 ((Preoperative: 0.125mg/kg, maintained at 0.075 mg · kg-1 · h-1, PCIA (sufentanil 2 µ g/kg+Esketamine 0.75mg/kg))

Sponsors

The Affiliated Cancer Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
25 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Age 25-65 ?American Society of Anesthesiologists grading I and II ?Body Mass Index 18-30kg/m2 ? Planned open surgery for cervical cancer patients under general anesthesia ? Surgical duration 2.5-4.5 hours ? Patient is willing to use patient controlled intravenous analgesia ? Sign informed consent form

Exclusion criteria

Exclusion criteria: ? Patients with known gastrointestinal motility disorders ? Previous history of major abdominal surgery (excluding cesarean section, appendix and cholecystectomy) ? Severe liver and kidney dysfunction ? Untreated or poorly controlled hypertensive patients (resting systolic blood pressure = 180mmHg and/or diastolic blood pressure = 100mmHg) ? Patients with hyperthyroidism without treatment or under treatment (pulse rate>90 times/minute, basal metabolism rate>20%, emotional instability, insomnia, weight loss and other symptoms) ? Patients with obvious ischemic heart disease ? Patients with elevated intraocular pressure, intracranial pressure, or mental illness ? Individuals who are allergic to esketamine or other anesthetics ? Patients with urinary tract obstruction, asthma, or epilepsy

Design outcomes

Primary

MeasureTime frame
The incidence of postoperative gastrointestinal dysfunction;

Secondary

MeasureTime frame
Daily I-FEED score for 7 days after surgery;Daily visual analogue scale (VAS) rest and exercise scores, as well as number of analgesic pump presses, 7 days after surgery;;The dosage of opioid drugs and the dosage of esketamine;;Rehabilitation progress indicators: first exhaust, defecation time, first oral intake time, and first time out of bed activity time;;The incidence of respiratory depression, hypotension, vomiting, nausea, and itching within 24 and 48 hours after surgery.;The incidence of multiple dreams, nightmares, hallucinations, mental disorders, restlessness, difficulty in orientation, blurred vision, tachycardia, and salivation within 24 and 48 hours after surgery.;

Countries

China

Contacts

Public ContactLi Jimei

The Affiliated Cancer Hospital of Guizhou Medical University

1575201617@qq.com+86 157 6160 1745

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026